Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Identification of LRP1+CD13+ human periosteal stem cells that require LRP1 for bone repair
Youngjae Jeong, Lorenzo Deveza, Laura Ortinau, Kevin Lei, John R. Dawson, Dongsu Park
Youngjae Jeong, Lorenzo Deveza, Laura Ortinau, Kevin Lei, John R. Dawson, Dongsu Park
View: Text | PDF
Research Article Bone biology Stem cells

Identification of LRP1+CD13+ human periosteal stem cells that require LRP1 for bone repair

  • Text
  • PDF
Abstract

Human periosteal skeletal stem cells (P-SSCs) are critical for cortical bone maintenance and repair. However, their in vivo identity, molecular characteristics, and specific markers remain unknown. Here, single-cell sequencing revealed human periosteum contains SSC clusters expressing known SSC markers, podoplanin (PDPN) and PDGFRA. Notably, human P-SSCs, but not bone marrow SSCs, selectively expressed identified markers low density lipoprotein receptor-related protein 1 (LRP1) and CD13. These LRP1+CD13+ human P-SSCs were perivascular cells with high osteochondrogenic but minimal adipogenic potential. Upon transplantation into bone injuries in mice, they preserved self-renewal capability in vivo. Single-cell analysis of mouse periosteum further supported the preferential expression of LRP1 and CD13 in Prx1+ P-SSCs. When Lrp1 was conditionally deleted in Prx1 lineage cells, it led to severe bone deformity, short stature, and periosteal defects. By contrast, local treatment with an LRP1 agonist at the injury sites induced early P-SSC proliferation and bone healing. Thus, human and mouse periosteum contains unique osteochondrogenic stem cell subsets, and these P-SSCs express specific markers, LRP1 and CD13, with a regulatory mechanism through LRP1 that enhances P-SSC function and bone repair.

Authors

Youngjae Jeong, Lorenzo Deveza, Laura Ortinau, Kevin Lei, John R. Dawson, Dongsu Park

×

Figure 10

Treatment with LRP1 agonist promotes periosteal cell proliferation and bone injury healing.

Options: View larger image (or click on image) Download as PowerPoint
Treatment with LRP1 agonist promotes periosteal cell proliferation and b...
(A) Images showing human periosteal cells treated with control or LRP1 agonist α2-macroglobulin (α2M) (10 nM), on day 1 and day 6. Quantitative measurement of number of cells in fold-change relative to day 0 shows that the α2M-treated group has significantly higher cell numbers compared with the control (P < 0.01) (n = 3). 10x original magnification. (B) Calvarial injuries in Prx1CreER-GFP Rosa26tdTomato mice (4- to 5-week-old, tamoxifen at P8–P10) were treated with α2M mixed with Matrigel (2 μL at 10 ng/μL of Matrigel), or Matrigel alone (control), at days 0, 2, and 4. The presence of Prx1-GFP+ and Tomato+ cells and bone healing were assessed by sequential in vivo intravital imaging at days 7 and 14 after injury. Bone, blue (n = 3). (C) Representative μCT images of tibial drill hole injury after 7 days of treatment with Matrigel control (left) or α2M mixed with Matrigel (right) at days 0, 2, and 4. 10x original magnification. (D) Quantification of μCT scans showing bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular spacing (Tb.Sp) (n = 5). Data presented as mean ± SD. **P < 0.01 by 2-tailed Student’s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts